Immunotherapy of established tumors using bone marrow transplantation with antigen gene–modified hematopoietic stem cells
Yan Cui(Augusta University), Katharine A. Whartenby(UK Dementia Research Institute), Ivan Borrello(Tampa General Hospital), Curt I. Civin(University of Maryland, Baltimore), Ephraim J. Fuchs(Johns Hopkins University), Drew M. Pardoll(Bloomberg (United States)), Erin Straley(Sidney Kimmel Comprehensive Cancer Center), Linzhao Cheng(University of Science and Technology of China), Hyam I. Levitsky(Century Therapeutics (United States)), Stephen P. Schoenberger(La Jolla Institute for Immunology), Kevin Gorski(Amgen (United States)), Erin S. Kelleher(University of Houston)
Cited by 60
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
|New England Journal of Medicine|2015|9.4k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k